Compare Stocks → These AI trades triggered this morning (545% return) (From Prosper Trading Academy) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AZRXNASDAQ:CLSNNASDAQ:LMNLNASDAQ:VRPX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAZRXAzurRx BioPharma$2.73-9.6%$4.04$3.36▼$26.30$25.46M1.51628,703 shs45,267 shsCLSNImunon$2.22$1.80▼$15.75$13.91M2.27150,471 shs711 shsLMNLLiminal BioSciences$8.50+0.1%$8.47$3.10▼$8.50$26.35M1.0363,470 shs5,000 shsVRPXVirpax Pharmaceuticals$3.07+5.1%$3.70$2.40▼$11.77$3.59M1.3820,169 shs3,207 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAZRXAzurRx BioPharma-3.21%+6.34%-23.93%-38.99%+5.96%CLSNImunon0.00%0.00%0.00%0.00%0.00%LMNLLiminal BioSciences0.00%0.00%0.00%0.00%+27.44%VRPXVirpax Pharmaceuticals-7.12%-26.60%-26.03%-7.72%-57.00%Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (Ad)The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAZRXAzurRx BioPharmaN/AN/AN/AN/AN/AN/AN/AN/ACLSNImunonN/AN/AN/AN/AN/AN/AN/AN/ALMNLLiminal BioSciencesN/AN/AN/AN/AN/AN/AN/AN/AVRPXVirpax PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAZRXAzurRx BioPharmaN/AN/AN/AN/ACLSNImunonN/AN/AN/AN/ALMNLLiminal BioSciencesN/AN/AN/AN/AVRPXVirpax PharmaceuticalsN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAZRXAzurRx BioPharmaN/AN/AN/AN/A($0.76) per shareN/ACLSNImunon$500K0.00N/AN/A$9.66 per share0.00LMNLLiminal BioSciences$310K85.00N/AN/A$8.97 per share0.95VRPXVirpax PharmaceuticalsN/AN/AN/AN/A$1.65 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAZRXAzurRx BioPharma-$32.67M-$11.50N/AN/AN/AN/A-482.96%-258.47%N/ACLSNImunon-$20.77MN/A0.00N/AN/A-5,229.80%-50.18%-36.94%N/ALMNLLiminal BioSciences$380K$0.2929.31∞N/A248.35%-88.44%-64.15%N/AVRPXVirpax Pharmaceuticals-$15.19M-$11.70N/A∞N/AN/A-169.04%-106.39%5/10/2024 (Estimated)DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAZRXAzurRx BioPharmaN/AN/AN/AN/AN/ACLSNImunonN/AN/AN/AN/AN/ALMNLLiminal BioSciencesN/AN/AN/AN/AN/AVRPXVirpax PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAZRXAzurRx BioPharmaN/A1.331.33CLSNImunon0.136.526.52LMNLLiminal BioSciences0.022.782.78VRPXVirpax PharmaceuticalsN/A1.251.25OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAZRXAzurRx BioPharma6.27%CLSNImunon12.97%LMNLLiminal BioSciences0.66%VRPXVirpax Pharmaceuticals32.23%Insider OwnershipCompanyInsider OwnershipAZRXAzurRx BioPharma7.30%CLSNImunon4.66%LMNLLiminal BioSciences2.20%VRPXVirpax Pharmaceuticals6.23%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAZRXAzurRx BioPharma129.33 million8.65 millionNot OptionableCLSNImunon277.10 million6.77 millionOptionableLMNLLiminal BioSciences2513.10 million3.04 millionNot OptionableVRPXVirpax Pharmaceuticals71.17 million1.10 millionNot OptionableAZRX, LMNL, VRPX, and CLSN HeadlinesSourceHeadlineVRPX Stock Earnings: Virpax Pharmaceuticals Misses EPS for Q4 2023investorplace.com - April 24 at 3:06 PMVirpax Pharmaceuticals Set for Transformative Year with High Hopes for Non-Addictive Pain Management Solutionsmsn.com - April 2 at 11:02 AMVirpax Pharmaceuticals Reports 2023 Year-End Resultsbusinesswire.com - March 26 at 7:30 AMVirpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Pricefinance.yahoo.com - February 27 at 10:21 AMVirpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Pricebusinesswire.com - February 27 at 7:31 AMVirpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.businesswire.com - February 27 at 7:30 AMVirpax Pharmaceuticals Reports Promising Results in Probudur Pilot Studymsn.com - February 12 at 7:33 AMAnalysts Offer Insights on Healthcare Companies: Virpax Pharmaceuticals (VRPX) and I-MAB (IMAB)markets.businessinsider.com - February 9 at 7:40 AMAnalysts Have Conflicting Sentiments on These Healthcare Companies: Vertex Pharmaceuticals (VRTX) and EyePoint Pharmaceuticals (EYPT)markets.businessinsider.com - February 7 at 3:59 PMVirpax Pharmaceuticals Announces Preliminary Results of ProbudurTM Pilot Study with the U.S. Army Institute of Surgical Researchpharmiweb.com - February 7 at 10:56 AMVirpax Pharmaceuticals Inc (VRPX)investing.com - January 23 at 1:47 PMVirpax Pharmaceuticals shareholders okay reverse stock splitmsn.com - December 29 at 7:54 PMTitan Pharmaceuticals to conduct 1-for-20 reverse stock splitmsn.com - December 28 at 6:06 PMVRPX Virpax Pharmaceuticals, Inc.seekingalpha.com - November 22 at 3:08 PMPromising Pipeline Developments and Market Opportunities Drive Buy Rating for Virpax Pharmaceuticalsmarkets.businessinsider.com - November 18 at 12:51 AMVirpax Pharmaceuticals gets non-compliance notice from Nasdaqmsn.com - November 17 at 9:20 AMVirpax Pharmaceuticals CEO and Chairman resigns on ongoing litigationmsn.com - November 17 at 9:20 AMVirpax Pharmaceuticals Announces Leadership Transitionfinance.yahoo.com - November 17 at 9:20 AMVirpax Pharmaceuticals Announces Notification from Nasdaq Related to Delayed Form 10-Q Filingfinance.yahoo.com - November 17 at 9:20 AMVirpax Pharmaceuticals GAAP EPS of -$0.51msn.com - November 15 at 7:29 PMVirpax Pharmaceuticals Announces that Envelta™ Remains on Track for Trial in Humans Following FDA Reviewfinance.yahoo.com - October 31 at 10:01 AMAnalysts Are Bullish on These Healthcare Stocks: Virpax Pharmaceuticals (VRPX), Kura Oncology (KURA)markets.businessinsider.com - September 28 at 4:00 PMVirpax Pharmaceuticals Announces Results of Probudur™ Dose Escalation Studiesfinance.yahoo.com - September 27 at 1:53 PMVirpax Pharmaceuticals to Present at the LD Micro Main Event XVIfinance.yahoo.com - September 26 at 2:19 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAzurRx BioPharmaNASDAQ:AZRXAzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product programs include MS1819, FW-1022: COVID-19 GI infections, and FW-420: Immune Checkpoint Inhibitor Colitis. The company was founded on January 30, 2014 and is headquartered in Delray Beach, FL.ImunonNASDAQ:CLSNCelsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.Liminal BioSciencesNASDAQ:LMNLLiminal BioSciences Inc., a development stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company is developing LMNL6511, a selective antagonist for the G-protein coupled receptor 84, is expected to commence a Phase 1 clinical trial. It is also developing potential OXER1 antagonists and GPR40 agonists, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.Virpax PharmaceuticalsNASDAQ:VRPXVirpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise PES200, which enables the delivery of a metabolically labile peptide drug into the brain; AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.